WO2010124089A3 - Nepicastat for treating dependence - Google Patents

Nepicastat for treating dependence Download PDF

Info

Publication number
WO2010124089A3
WO2010124089A3 PCT/US2010/032052 US2010032052W WO2010124089A3 WO 2010124089 A3 WO2010124089 A3 WO 2010124089A3 US 2010032052 W US2010032052 W US 2010032052W WO 2010124089 A3 WO2010124089 A3 WO 2010124089A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
nepicastat
dependence
substance
methods
Prior art date
Application number
PCT/US2010/032052
Other languages
French (fr)
Other versions
WO2010124089A2 (en
Inventor
Michael Mulqueen
Mark Moran
Original Assignee
Synosia Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics, Inc. filed Critical Synosia Therapeutics, Inc.
Publication of WO2010124089A2 publication Critical patent/WO2010124089A2/en
Publication of WO2010124089A3 publication Critical patent/WO2010124089A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with nepicastat in combination with psychosocial therapy. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.
PCT/US2010/032052 2009-04-22 2010-04-22 Methods for treating dependence WO2010124089A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17155209P 2009-04-22 2009-04-22
US61/171,552 2009-04-22

Publications (2)

Publication Number Publication Date
WO2010124089A2 WO2010124089A2 (en) 2010-10-28
WO2010124089A3 true WO2010124089A3 (en) 2010-12-16

Family

ID=42829358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/032052 WO2010124089A2 (en) 2009-04-22 2010-04-22 Methods for treating dependence

Country Status (1)

Country Link
WO (1) WO2010124089A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016160715A1 (en) * 2015-03-27 2016-10-06 Markel Dan Method for treating addiction
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009954A (en) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 Neurocognitive Disorder, How to Treat Chronic Pain and Reduce Inflammation
CN111018663A (en) * 2019-12-02 2020-04-17 苏州凯瑞医药科技有限公司 Nepitastat important intermediate and enzyme catalytic synthesis method thereof
KR20240096817A (en) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 Deuterated tryptamine derivatives and methods of use
WO2023168022A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocybin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021055A1 (en) * 2007-08-06 2009-02-12 Synosia Therapeutics, Inc. Methods for treating dependence

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021055A1 (en) * 2007-08-06 2009-02-12 Synosia Therapeutics, Inc. Methods for treating dependence

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"ClinicalTrials Identifier: NCT00656357. Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers", 10 April 2008 (2008-04-10), XP002604280, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00656357/2008_04_10> [retrieved on 20101008] *

Also Published As

Publication number Publication date
WO2010124089A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
WO2010124089A3 (en) Nepicastat for treating dependence
PH12015502210A1 (en) Method for treating dependence
IL220040A0 (en) Methods and low dose regimens for treating red blood cell disorders
WO2012012467A3 (en) Modulation of nuclear-retained rna
WO2008153730A3 (en) Method for treating proliferative disorders associated with mutations in c-met
WO2009124133A3 (en) Security features for a medical infusion pump
EP2362726A4 (en) Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2012061558A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2012061374A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2012018790A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2009139921A3 (en) Microorganisms for preventing and treating neoplasms accompanying cellular therapy
IL207792A0 (en) Methods, dosage forms, and kits for administering ziprasidone without food
EP2413837A4 (en) Methods for treating myofascial, muscle, and/or back pain
WO2012142300A3 (en) Methods of determining a treatment protocol for and/or a prognosis of a patient&#39;s recovery from a brain injury resulting from a hypoxic event
IL215583A0 (en) Methods for preventing and/or treating lysosomal storage disorders
WO2010132622A3 (en) Anticd20-cpg conjugates and methods of treating b cell malignancies
EP2073843A4 (en) Methods of diagnosing, treating, or preventing plasma cell disorders
EP2608786A4 (en) Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
MX2012014163A (en) Methods of treatment.
WO2010054328A3 (en) Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2011050351A3 (en) Methods and kits used in identifying glioblastoma
WO2012082821A3 (en) Melanoma treatments
BRPI0819195A2 (en) methods for treating scleroderma in a patient in need of such treatment and for alleviating one or more of the symptoms associated with scleroderma in a patient in need of such treatment.
PL2446276T3 (en) Methods for determining the oncogenic condition of cell, uses thereof, and methods for treating cancer
WO2008115478A3 (en) Method of cancer detection and treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10715637

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10715637

Country of ref document: EP

Kind code of ref document: A2